Evaluation of system therapies for AD

In addition to conventional immunosuppressants, several monoclonal antibodies (biologics) and Janus kinase inhibitors (JAK-i) are now approved for the systemic treatment of atopic dermatitis (AD) in Switzerland. The primary objective of the TREATswitzerland registry study is to evaluate the use, efficacy and safety of currently available treatment options in a real-life setting throughout the country.